metformin has been researched along with Retinal Vein Occlusion in 1 studies
Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.
Retinal Vein Occlusion: Blockage of the RETINAL VEIN. Those at high risk for this condition include patients with HYPERTENSION; DIABETES MELLITUS; ATHEROSCLEROSIS; and other CARDIOVASCULAR DISEASES.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Previous studies have found that metformin can reduce cardiovascular risk, but its association with retinal vein occlusion (RVO) is unknown." | 7.85 | Protective effect of metformin against retinal vein occlusions in diabetes mellitus - A nationwide population-based study. ( Chen, SJ; Chiou, SH; Hsu, CC; Hwang, DK; Lin, TC; Peng, CH; Wang, ML, 2017) |
| "Previous studies have found that metformin can reduce cardiovascular risk, but its association with retinal vein occlusion (RVO) is unknown." | 3.85 | Protective effect of metformin against retinal vein occlusions in diabetes mellitus - A nationwide population-based study. ( Chen, SJ; Chiou, SH; Hsu, CC; Hwang, DK; Lin, TC; Peng, CH; Wang, ML, 2017) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lin, TC | 1 |
| Hwang, DK | 1 |
| Hsu, CC | 1 |
| Peng, CH | 1 |
| Wang, ML | 1 |
| Chiou, SH | 1 |
| Chen, SJ | 1 |
1 other study available for metformin and Retinal Vein Occlusion
| Article | Year |
|---|---|
Protective effect of metformin against retinal vein occlusions in diabetes mellitus - A nationwide population-based study.
Topics: Aged; Diabetes Complications; Female; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Ret | 2017 |